BioCorRx Enters Agreement with National Institute on Alcohol Abuse and Alcoholism

ANAHEIM, CA, Dec. 14, 2017 -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addiction, today announced that it has entered into an agreement with the National Institute on Alcohol Abuse and Alcoholism (NIAAA). As noted on their website, “NIAAA is one of the 27 institutes and centers that comprise the National Institutes of Health (NIH). NIAAA supports and conducts research on the impact of alcohol use on human health and well-being. It is the largest funder of alcohol research in the world.” The purpose of the agreement is to share information and potentially collaborate on further research, development and commercialization of the Company’s therapies and programs for the treatment of alcohol use disorder. 

Brady Granier, CEO, President, and Director of BioCorRx, commented, “We are pleased to have another important government agency interested in our naltrexone implant, BICX102. NIAAA leads the national effort to reduce alcohol-related problems and we are happy to engage with them in preparation for our Pre-IND meeting next January. Naltrexone is already approved in other forms for the treatment of alcohol and opioid use disorders and our desire is to gain approval for both indications for BICX102. We look forward to exploring the opportunities for collaborating with NIAAA on this important product. Alcohol use disorder is a very large issue that often gets lost in the current opioid epidemic. It needs more attention and options for treatment.”

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.
[email protected]
714-462-4880

Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
[email protected]